Front. Oncol.Frontiers in OncologyFront. Oncol.2234-943XFrontiers Media S.A.10.3389/fonc.2023.1343027OncologyCorrectionCorrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib armsGrünwaldViktor1*PowlesThomas2EtoMasatoshi3KopyltsovEvgeny4RhaSun Young5PortaCamillo6MotzerRobert7HutsonThomas E.8Méndez-VidalMaría José9HongSung-Hoo10WinquistEric11GohJeffrey C.12MarotoPablo13BuchlerTomas14TakagiToshio15BurgentsJoseph E.16PeriniRodolfo17HeCixin18OkparaChinyere E.19McKenzieJodi20ChoueiriToni K.211Clinic for Medical Oncology and Clinic for Urology, University Hospital Essen, Essen, Germany2Barts Cancer Institute and the Royal Free Hospital, Queen Mary University of London, London, United Kingdom3Department of Urology, Kyushu University, Fukuoka, Japan4State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia5Department of Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea6Department of Biomedical Sciences and Human Oncology, University of Bari ‘A. Moro’, Bari, Italy7Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States8Medical Oncology, Texas Oncology, Dallas, TX, United States9Department of Oncology, Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) Hospital Universitario Reina Sofía, Córdoba, Spain10Department of Urology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea11Department of Oncology, University of Western Ontario, London, ON, Canada12ICON Research, South Brisbane & University of Queensland, St Lucia, QLD, Australia13Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain14Department of Oncology, Charles University and Thomayer University Hospital, Prague, Czechia15Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan16Global Clinical Development, Merck & Co., Inc., Rahway, NJ, United States17Clinical Research, Merck & Co., Inc., Rahway, NJ, United States18Biostatistics, Eisai Inc., Nutley, NJ, United States19Clinical Research, Eisai Ltd., Hatfield, United Kingdom20Clinical Research, Eisai Inc., Nutley, NJ, United States21Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
Edited and Reviewed by: Umang Swami, The University of Utah, United States
*Correspondence: Viktor Grünwald, Viktor.Gruenwald@uk-essen.de
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms by Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE, Méndez-Vidal MJ, Hong S-H, Winquist E, Goh JC, Maroto P, Buchler T, Takagi T, Burgents JE, Perini R, He C, Okpara CE, McKenzie J and Choueiri TK (2023) Front. Oncol. 13:1223282. doi: 10.3389/fonc.2023.1223282renal cell carcinomalenvatinibpembrolizumabsunitinibbone metastasesliver metastaseslung metastasessarcomatoid histologysection-in-acceptanceGenitourinary Oncology
In the published article, there was an error in the legend for Figure 3 and Supplementary Table 1 as published. Clarification that objective response rates and complete response rates were calculated based on the number of patients in each listed subgroup was omitted. The corrected legend of both appears below.
ORRa and Odds Ratios for Lenvatinib + Pembrolizumab Versus Sunitinib Treatment in Subgroups of Interest. aAs assessed by IRC per RECIST v1.1. bPercents were calculated based on listed subgroups. CI, confidence interval; CR, complete response; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; IRC, independent review committee; ITT, intention to treat; L+P, lenvatinib + pembrolizumab; MSKCC, Memorial Sloan Kettering Cancer Center; ORR, objective response rate; RECIST v1.1, Response Evaluation Criteria In Solid Tumors version 1.1; S, sunitinib.
“aAs assessed by IRC per RECIST v1.1. bPercents were calculated based on listed subgroups.”
In the published article, there was an error in Figure 3 and Supplementary Table 1 as published. For both, percentages in the “complete response” column were incorrectly calculated as the number of patients with a complete response in each subgroup divided by all patients in the respective treatment arm (n=355 for lenvatinib + pembrolizumab; n=357 for sunitinib) instead of being divided by the number of patients in each applicable subgroup.
The corrected Figure 3 and its captions (also corrected per the above to “aAs assessed by IRC per RECIST v1.1. bPercents were calculated based on listed subgroups.”) appear below.
The text did not account for the revisions made to the complete response rate mentioned above.
A correction has been made to Section 3.2.3 (Objective response), paragraph 2. This sentence previously stated:
“As expected, the rates of CRs were higher in patients without baseline bone metastases or baseline liver metastases, in patients who had baseline lung metastases, and in patients who had a prior nephrectomy. While the number of patients with sarcomatoid features was small, the rates of CRs in patients without sarcomatoid features was higher than those of patients with sarcomatoid features.”
The corrected sentence appears below:
“As expected, the rates of CRs were higher in patients without baseline bone metastases, and in patients who had a prior nephrectomy. CR rates were similar irrespective of whether or not patients had baseline liver metastases.”
The Supplementary Table 1 has been updated directly in the original article.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.